Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates. The update highlighted three autoimmune disease bets: CAPTIVATE, a Phase 3 trial testing claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), MoMeNtum for multifocal motor neuropathy, and EMERGE for generalized myasthenia gravis.
CAPTIVATE's interim data showed a 75% response rate in 40 participants, surpassing the 50% target. No serious infections or drug-induced lupus symptoms were reported. The company launched EMERGE in June and completed MoMeNtum, with top-line results expected by December. Dianthus has $1.2 billion in cash, funding operations until 2030.
Research and development spending increased to $48.7 million, while general and administrative costs rose to $13.6 million. Net loss widened to $50.2 million. Hedge fund ownership decreased, and short interest sits at 17.27% of float. The market treats the clinical wins cautiously due to the multi-year path to any regulatory filing.
While Dianthus has more clinical validation, the widening net loss suggests patience is required for the bull case to hold.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
